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Selective Agonists of Estrogen Receptor Isoforms
New Perspectives for Cardiovascular Disease
Chiara Bolego, Elisabetta Vegeto, Christian Pinna, Adriana Maggi, Andrea Cignarella
Abstract—The cloning of estrogen receptors (ERs) and generation of ER-deficient mice have increased our understanding
of the molecular mechanisms underlying the cardiovascular effects of estrogen. It is conceivable that clinical trials of
estrogens so far failed to improve cardiovascular health because of the poor ER isoform selectivity and tissue specificity
of endogenous hormones as well as incorrect treatment timing and regimens. Tissue-selective ER modulators (SERMs)
may be safer agents than endogenous estrogens for cardiovascular disease. Yet, designing isoform-selective ER ligands
(I-SERMs) with agonist or antagonist activity is required to pursue improved pharmacological control of ERs, especially
taking into account emerging evidence for the beneficial role of vascular ER activation. Ideally, the quest for unique
ER ligands targeted to the vascular wall should lead to compounds that merge the pharmacological profiles of SERM
and I-SERM agents. This review highlights the current bases for and approaches to selective ER modulation in the
cardiovascular system. (Arterioscler Thromb Vasc Biol. 2006;26:2192-2199.)
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Coronary artery disease (CAD) accounts for one-third ofall deaths in postmenopausal women.1 A potential role
for estrogen in cardiovascular disease (CVD) protection has
been long suggested by the observations that women have a
reduced relative CVD risk as compared with men, but this
benefit is lost after menopause, when circulating estrogen
levels decrease dramatically.2 Since the cloning of estrogen
receptors (ERs) and generation of ER knockout animals,
several mediators and mechanisms have been identified
attesting a beneficial role for estrogen on the cardiovascular
system.3,4 When translated into the clinical setting, however,
the value of observational and experimental studies has been
disputed. In fact, the HERS (Heart and Estrogen/progestin
Replacement Study) trial showed no benefit for hormone
therapy with respect to cardiovascular events,5 and the
estrogen/medroxyprogesterone arm of the Women’s Health
Initiative study was terminated prematurely because of an
increased risk of CVD events.6
The disappointing results from clinical trials dimmed the
optimistic perspective raised by preclinical studies. Yet, the
body of evidence accrued by fundamental research in favor of
beneficial cardiovascular effects of estrogen is too compel-
ling to be ignored. To effectively translate this evidence from
fundamental research into clinical practice, clearly there is a
need to reappraise the molecular mechanism of ER activation
and the specific physiological role of ER isoforms to identify
more specific targets for pharmacological intervention. We
focus here on the available molecular and pharmacological
evidence supporting the opportunity to design agents com-
bining ER-isoform and tissue selectivity targeted to the
cardiovascular system, which may provide therapeutic bene-
fits through direct vascular effects and control of vascular
inflammation with limited adverse effects elsewhere.
Estrogen Receptors at Work
The biological actions of estrogen are largely mediated by 2
distinct ER isoforms, namely ER and ER, that are widely
distributed in tissues including the cardiovascular system
(Figure 1A). The molecular pathways of ER activation have
been deeply investigated. Following ligand binding, the ER
undergoes conformational changes and biochemical modifi-
cations that induce release of inhibitory proteins (heat shock
proteins), receptor dimerization, and interaction with DNA.
In fact, nuclear ER acts as a transcription factor that modu-
lates gene expression by directly binding to DNA at specific
estrogen response elements (EREs) (Figure 1B). ER is also
able to hinder transcription of promoters lacking EREs
indirectly by interacting with nuclear transcription factors
(Figure 1C).7 ER transcriptional activity may be regulated by
intracellular signaling pathways even in the absence of
estrogenic ligands (Figure 1D). For example, activation of
growth factor receptors stimulates ER-mediated transcrip-
tion.8 Ligand-independent ER activation has been recently
demonstrated in vivo using transgenic reporter mice engi-
neered to allow noninvasive imaging of ER transcriptional
activity in all tissues of the alive mouse.9
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ERs regulate transcription of target genes in the nucleus
also by recruiting coregulatory proteins such as coactivators.
The distribution and relative abundance of coregulators pro-
mote the tissue-selective effects of drugs affecting ER func-
tion. By way of example, the steroid receptor coactivator-3 is
highly expressed in vascular smooth muscle cells (SMCs) and
appears to facilitate ER-dependent vasoprotective effects
during vascular injury.10 The structural domains responsible
for the interaction between ER and coregulatory proteins are
scarcely homologous comparing ER and ER, which ex-
plains the different ability to interact with coregulators11 and
the diverse transcriptional responses evoked by these iso-
forms.7,12 In addition, ER may inhibit ER action by
forming heterodimers, indicating a “ying–yang” relationship
between the 2 isoforms.13 Thus, the relative expression of ER
isoforms drives the chain of cellular events mediated by ER
activation.
As shown in Figure 1E, rapid nongenomic effects also
follow ER–ligand interactions. These seem to be mediated by
a receptor isoform, either distinct or identical to cloned ERs,
localized at the plasma membrane (Figure 1B).14 Recently, an
intracellular estrogen-binding site located on the endoplasmic
reticulum has been described as a G protein–coupled receptor
mediating intracellular calcium mobilization.15 Therefore, it
appears that various ER forms expressed in vascular cells
may be particularly efficient signal transducers and may use
classical receptor domains for membrane targeting and inser-
tion. The rapid regulation of nongenomic signal transduction
pathways may ultimately influence the outcome of steroid-
regulated gene expression, thus implying that rapid extranu-
clear and nuclear actions of ERs are coordinately integrated.16
The multiple biomedical ramifications of ER-mediated
cellular activation have been reviewed recently.17
Pharmacological Modulation of ERs
Understanding how activated ERs elicit organ-specific effects
is essential to design pharmacological agents reproducing
estrogenic effects in target tissues without sharing untoward
Figure 1. Estrogen receptors at work in the cardiovascular system. A, Two receptor isoforms, ER and ER, and splicing variants were
identified. DBD indicates DNA-binding domain; LBD, ligand-binding domain. B through E, Mechanisms of action of ERs: ERE-
dependent (B) and -independent (C) transcriptional activity induced by receptor ligands or by ER-unrelated signals (D) and cytoplasmic
mediators of ER nongenomic activity (E). See text for further details.
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effects elsewhere. Because the endogenous ER agonist 17-
estradiol has the same binding affinity for ER and ER in
tissues,18 2 approaches have been envisioned to accomplish
selective modulation of ER activity: nonsteroidal tissue-
selective ER modulators (SERMs) and selective ligands
endowed with higher affinity for either ER isoform, which we
here define as I-SERMs. The latter agents have been devel-
oped recently and are currently undergoing extensive evalu-
ation (Table).
SERMs act by interacting with ER but differ from estro-
gens by eliciting agonist or antagonist effects depending on
the target tissue.19,20 The most representative compounds of
this class are tamoxifen and raloxifene (Figure 2). It is
believed that selective ER modulation can be pursued be-
cause the conformational changes of ER induced by synthetic
ligands may differ from those induced by 17-estradiol.21,22
In particular, the interaction of agonists at the activating
function (AF)-2 region of ER protein results in the recruit-
ment of coactivators (Figure 1A), whereas antagonists favor
recruitment of corepressors.20,22,23 Binding a SERM impairs
AF-2 activity, whereas AF-1 is free to interact with other
proteins, promoting the interaction of DNA-bound ER. Thus,
based on available coregulators, the ER-bound SERM will act
as a partial or even full agonist. In contrast, in cells lacking
proteins interacting with AF-1, the SERM will prevent
activation by estrogens and will therefore behave as a full
antagonist.24 Yet, the molecular mechanisms underlying the
tissue specificity of SERM effects are not completely
elucidated.
Since the discovery of ER, a major effort was made to
develop compounds acting specifically on either ER subtype
(Figure 2). The diarylpropionitrile DPN is a potent ER
agonist with a 30- to 70-fold selectivity over ER.25 Members
of the triarylpyrazole class such as propylpyrazole trisphenol
(PPT) are 400-fold more potent on ER than on ER.26 By
introducing basic side chain substituents such as those found
in tamoxifen, ER selective antagonists have also been
synthesized.27 I-SERMs induce specific ER conformations
exposing interaction surfaces for coregulator recruitment
quite different from 17-estradiol.11 It is therefore conceiv-
able that I-SERMs feature cell specificity of action, which
should be investigated to develop more selective and specific
pharmacological agents with estrogenic activity. Ideally, the
major accomplishment of a quest for unique ER ligands
would be the design of compounds (either ER agonists or
antagonists or partial agonists) endowed with ER-subtype
specificity and tissue- or even cell-specific action.
Cardiovascular Action of Selective
ER Ligands
ER and ER are widely distributed in the cardiovascular
system.28,29 By regulating many genes involved in vascular
biology, ERs exert direct effects on vascular cells and protect
Selective ER Ligands
Compounds and Examples
I-SERMs
ER selective: PPT
ER selective: DPN
Selective for membrane ER: ?
SERMs
Raloxifene, tamoxifen, and many more
SERMs of the future
Selective for isoform and tissue
Selective for coregulator proteins
Pathway-selective ER ligands (WAY 169916)
Figure 2. Structure of representative selective ER agonists (PPT, DPN), selective ER antagonists (MPP), and SERMs already in clinical
use (tamoxifen and raloxifene).
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from vascular injury.3,30 ER isoforms may have differential
activity, as shown for plasminogen activator inhibitor (PAI)-1
promoter activity, which is increased by ER through an
estrogen-dependent pathway and suppressed by ER through
an estrogen-independent mechanism.31 Yet, a systematic
approach aimed at defining precisely the differences in
vascular gene expression regulation by ER isoforms is lack-
ing. On the other hand, the rapid vasorelaxant effect of
estrogen mainly results from endothelial NO synthase
(eNOS) activation on the plasma membrane of endothelial
cells.32 This non-nuclear estrogen-signaling pathway involves
direct interaction of ER with phosphatidylinositol
3-kinase.14 ER activation in turn has been shown to rapidly
enhance thrombin-induced aggregation in human platelets.33
Functional Role of ER Isoforms: Lessons From
Animal Models of Targeted ER Deletion
The generation of knockout (KO) mice lacking ER or ER
has provided insights into their specific role in the cardiovas-
cular system.34 Overall, ER appears to mediate most car-
dioprotective actions of estrogen including nongenomic va-
sodilation. Estrogen treatment increases basal NO production
in the aorta only in mice expressing functional ER,35 and the
vasorelaxation to 17-estradiol becomes more pronounced in
ER-deficient mice.36 Because the NO-mediated vasodilator
response to intraarterial 17-estradiol in vivo is absent in
double ER-ER KO mice,37 ER appears to primarily
modulate NO-mediated vasorelaxation, whereas ER may
sway ER activity. Estrogens also increase urinary excretion
of cyclooxygenase (COX)-2–derived prostacyclin metabo-
lites in ER but not ER KO mice.38 An indirect interaction
between ER and DNA via activator protein (AP)-2 has been
shown to positively regulate COX-1.39
In mice with genetic ER deletion, the cardioprotective
role of estrogen in ischemia/reperfusion injury is lost40 and no
detectable effects on vascular injury are observed after
estrogen treatment.41,42 Of note, the protective mechanisms of
estrogen in brain ischemia are also abolished by ER dele-
tion.43 ER activation provides sex-specific protection be-
cause females develop less atherosclerosis than males in
wild-type but not ER-deficient mice.44 Conversely, genetic
deletion of ER results in the development of hypertension,45
which may be an indirect effect possibly attributable to
systemic hypoxia.46 In view of the differential involvement of
ER isoforms in vascular protection, selective pharmacologi-
cal intervention on ER represents a promising therapeutic
strategy.
ER Number and Relative Expression Pattern
Several factors may affect the relative abundance and/or
specific distribution of ER and ER. This may ultimately
affect the pharmacological action of ER ligands (Figure 1).
For instance, a significant association was found between ER
number and endothelial function, suggesting that a decreased
ER number represents a risk factor for CVD.47 ER and ER
expression in vascular cells is regulated by endocrine status48
and pathological conditions including inflammation,49 diabe-
tes,49 and aortic stenosis.50 ER protein expression seems to
correlate with coronary calcification as an index of athero-
sclerosis in humans.51 In vascular SMCs from human athero-
sclerotic lesions, estradiol shows antiproliferative effects in
ER-positive, but not ER-positive, cells, with decreased
levels of ER being associated with progression of athero-
sclerotic damage.52 Thus, ER expression pattern is regulated
under pathophysiological conditions.
Endogenous estrogens themselves finely tune ER expres-
sion in vascular cells. In human aortic SMCs, estrogen
downregulates the expression of ER but not ER.53 Con-
versely, all forms of ER in cerebral vessels decrease after
ovariectomy but increase significantly after chronic estrogen
treatment.54 The duration of estrogen deprivation may also
have a major impact on ER number and ultimately on
estrogen activity. Accordingly, we demonstrated that acute
ER-dependent arterial vasodilation vanishes in estrogen-
deprived rats.55 ER ligands may thus alter differently vascular
cell biology as estrogen deprivation and/or vascular disease
progress,56 thereby making the time at which pharmacologi-
cal treatment is started a crucial determinant of efficacy
(timing hypothesis). Accordingly, recent publications from
the Nurses’ Health Study57 and the Women’s Health Initia-
tive58 indicate a potential protective effect of estrogen in early
postmenopausal women.
Vascular Action of SERMs and I-SERMs
Whereas the vascular effects of endogenous ER ligands have
been described in some detail,59 the use of established and
novel selective ER ligands holds promise to evoke beneficial
vascular responses with limited undesired effects in nonvas-
cular tissues.
Raloxifene mediates acute ER- and endothelium-
dependent vasorelaxation in rabbit coronary arteries.60 When
chronically administered to ovariectomized rats, the drug
stimulates eNOS expression61 and lowers ischemia suscepti-
bility by increasing heart NO generation.62 Hypertension-
induced endothelial dysfunction was significantly improved
after raloxifene treatment through enhanced NOS activity and
reduced reactive oxygen species production.63 Furthermore,
endothelial cells exposed to serum from raloxifene-treated
women show enhanced prostacyclin production.64 There is
also evidence for an ER-independent vasodilating effect of
raloxifene mediated by inhibition of L-type voltage-sensitive
Ca2 channels.65
Similar to estrogen, raloxifene has antiproliferative prop-
erties in vascular SMCs, probably via interaction with ER.66
In a model of rat carotid injury, raloxifene inhibits neointimal
thickening67 and fosters reendothelialization.68 In addition,
estrogen but not raloxifene reduces coronary artery plaque
size in ovariectomized monkeys fed an atherogenic diet,69
indicating that the vascular effects of estrogen and raloxifene
do not necessarily overlap. Thus, raloxifene may be a
promising agent for treating some aspects of CVD, although
its pharmacological effects are spread over multiple tissues.
At present, SERMs with targeted action to the cardiovascular
system are not available.
There are few studies with I-SERMs on cardiovascular
function. Our group recently demonstrated that both ER and
ER are expressed in endothelial cells of rat aorta, but only
selective ER agonists induce acute ER- and NO-dependent
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vasodilation.55 A role for ER in improving endothelial
dysfunction has been demonstrated in ovariectomized SHR
rats treated with the selective ER agonist Cpd1471.70
Accordingly, rabbits treated with the selective ER agonist
PPT are protected from ischemia/reperfusion injury, further
supporting a beneficial role for ER.71 The selective ER
agonist DPN acutely relaxed precontracted mesenteric arter-
ies from male rats,72 and the presence of ER apparently
inhibits ER-mediated NO relaxation,73 indicating that acute
responses to selective ER agonists may vary dependent on the
vessel used.74 Studies addressing cardiovascular function
modulation by selective ER ligands in vivo are lacking to
date.
Clinical Studies
Epidemiological evidence indicates potential cardioprotective
effects of estrogens, whereas interventional studies do
not.5,6,58 Evidence for beneficial effects of SERMs on CVD
outcomes is so far limited.
The use of tamoxifen for the treatment of breast cancer
during 5 years of follow-up was associated with a reduced
risk of acute myocardial infarction in women,75 suggesting
that tamoxifen protects against CAD.76 The MORE trial,
which was designed to determine the effects of raloxifene on
vertebral fractures in women with osteoporosis, showed that
4-year treatment with raloxifene does not affect CV risk in the
overall cohort nor in any single year77 but does so in those
women with increased CVD risk at baseline.78 However, a
serious adverse event associated with raloxifene therapy is a
2-fold increase in the risk of venous thromboembolic events
compared with placebo.79 The RUTH trial randomized
10 101 postmenopausal women (mean age, 67.5 years) with
CAD or multiple risk factors for CAD to either 60 mg of
raloxifene daily or placebo for a median of 5.6 years. The
results show that raloxifene had no significant effect on the
primary end point, coronary events, but it did significantly
increase the risk of venous thromboembolism.80 Although the
drug had no effect on stroke overall, there was a significant
increase in death from stroke. Although reducing the risk of
hormone-positive breast cancer and vertebral fractures, the
benefits of raloxifene do not appear to outweigh the cardio-
vascular risks.
Antiinflammatory Action of ER Ligands
Inflammation develops concurrently with accumulation of
minimally oxidized low-density lipoprotein in the arterial
wall and is present at every stage of the atherosclerotic
process. 17-Estradiol is known to target several cell types
that drive the inflammatory process. Early studies indicate
that the hormone inhibits interleukin (IL)-1–mediated induc-
tion of endothelial cell adhesion molecules including mem-
brane E-selectin and vascular cell adhesion molecule
(VCAM)-1.81 We demonstrated that 17-estradiol is able to
block the synthesis of inducible NOS promoted by inflam-
matory stimuli in vascular82 and nonvascular tissues.83 The
early vascular injury response as a whole is attenuated by
17-estradiol, as shown by the reduced expression of adhe-
sion molecules, chemokines and proinflammatory cytokines
in rat carotid arteries, which in turn reduce leukocyte recruit-
ment and chemiotaxis.84 Recently, the molecular players
involved in estrogen action have been investigated, pointing
to the relevant role of ER. This receptor isoform inhibits
inflammatory gene transcription; our recent work linked this
effect with a unique mechanism of action among antiinflam-
matory drugs involving inhibition of nuclear factor (NF)-B
nuclear translocation.85 The relevance of the NF-B pathway
as a target of estrogen anti-inflammatory activity is further
underlined by the identification of pathway-selective ER
ligands, such as WAY-169916, which retain the ability to
antagonize the NF-B pathway while being devoid of clas-
sical estrogenic action on reproductive tissues (Table).86
Interestingly, WAY-169916 protects against cardiac ische-
mia/reperfusion injury, although displaying different activity
on cardiovascular end points as compared with 17-
estradiol.87 Accordingly, evidence has accumulated as to the
role of ER in preventing inflammatory-related cerebrovas-
cular and neural disease using ER-knockout mice and I-
SERMs.43,88–90 On the other hand, although ER-selective
ligands reduced clinical signs of inflammatory bowel disease
and rheumatoid arthritis,91 the specific role of ER in
inflammation is not yet clarified. Of note, estrogen antiin-
flammatory effects may rely on vascular health because ER
expression is regulated by oxidative stress.92,93 Accordingly,
the expression pattern of ER isoforms is altered in vascular
SMC from streptozotocin–diabetic as compared with normo-
glycemic rats.49
Thus, experimental evidence accumulated so far indicates
that additional benefits of SERMs and I-SERMs may be
anticipated if these compounds shared the antiinflammatory
activity of 17-estradiol on the innate immune system.
In humans, hormone therapy has a significant impact on
levels of inflammatory biomarkers.94 Yet, an important issue
in this regard is the route of administration, because trans-
dermal as opposed to oral estradiol administration does not
elevate C-reactive protein (CRP).94 Raloxifene does not
affect, whereas tamoxifen markedly reduces, plasma CRP95
and fibrinogen96 levels, probably by direct ER antagonism.
Although lowering inflammatory markers such as CRP ap-
pears to decrease cardiovascular risk, it is unclear whether
selective ER ligands may affect clinical end points through
such effects.97
Conclusions and Open Questions
Currently, ER appears to be a primary target for both
cardiovascular and inflammatory disease. We still have to
address the pharmacological limitations of poor ER-subtype
and tissue selectivity of physiological estrogens. A step
forward should come from basic research to better understand
how SERMs and I-SERMs work at the tissue level and how
ER function is altered under pathophysiological conditions.
An emerging determinant of therapeutic efficacy for ER
ligands is the cyclic or permanent change of ER expression
patterns in the vessel wall before and after menopause.56
Accordingly, clinical outcomes may be affected by vascular
health in individual patients, suggesting the importance of
treatment timing.98 So far, compounds fulfilling both criteria
of ER-subtype and tissue selectivity are lacking (Table).
Although the quest for such molecules still requires solid
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fundamental knowledge of ER molecular pharmacology as
well as extensive clinical testing of efficacy and safety, this
strategy represents the way ahead to exploit the benefits of
estrogenic compounds on the vascular wall while, at the same
time, limiting undue effects elsewhere.
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